Merck (MRK.N) said China's National Medical Products Administration has approved its long-acting monoclonal antibody injection, marketed as Anfuchang, for prevention of RSV-caused lower respiratory tract infection in newborns and infants who are ente

2026-06-15

Merck (MRK.N) said China's National Medical Products Administration has approved its long-acting monoclonal antibody injection, marketed as Anfuchang, for prevention of RSV-caused lower respiratory tract infection in newborns and infants who are entering or born into their first RSV season.